Key result
The Claret CE Pro cerebral protection device was feasible during TAVI, with a technical success rate of 60% for the first-generation and 87% for the second-generation device.
Why the study?
Is a novel cerebral embolic protection device feasible and safe in patients undergoing transcatheter aortic valve implantation?
Is a novel cerebral embolic protection device feasible and safe in patients undergoing transcatheter aortic valve implantation?
The first-in-human use of a novel cerebral protection device during TAVI demonstrated feasibility and safety, successfully capturing embolic debris in over half of the patients without procedural strokes.
Answers are grounded in this paper and cite their sources.
Supports further device development for TAVI embolic protection; randomized trials needed before clinical adoption.
AIMS: We describe the first-in-human experience with a novel cerebral embolic protection device used during transcatheter aortic valve implantation (TAVI). One current challenge of TAVI is the reduction of procedural stroke. Procedural mobilisation of debris is a known source of cerebral embolisation. Mechanical protection by transient filtration of cerebral blood flow might reduce the embolic burden during TAVI. We aimed to evaluate the feasibility and safety of the Claret CE Pro™ cerebral protection device in patients undergoing TAVI. METHODS AND RESULTS: Patients scheduled for TAVI were prospectively enrolled at three centres. The Claret CE Pro™ (Claret Medical, Inc. Santa Rosa, CA, USA) cerebral protection device was placed via the right radial/brachial artery prior to TAVI and was removed after the procedure. The primary endpoint was technical success rate. Secondary endpoints encompassed procedural and 30-day stroke rates, as well as device-related complications. Deployment of the Claret CE Pro™ cerebral protection device was intended for use in 40 patients, 35 devices were implanted into the aortic arch. Technical success rate with delivery of the proximal and distal filter was 60% for the first generation device and 87% for the second-generation device. Delivery times for the first-generation device were 12.4±12.1 minutes and 4.4 ± 2.5 minutes for the second-generation device (p<0.05). The quantity of contrast used related to the Claret CE Pro System was 19.6 ± 3.8 ml. Captured debris was documented in at least 19 of 35 implanted devices (54.3%). No procedural transient ischaemic attacks, minor strokes or major strokes occurred. Thirty-day follow-up showed one minor stroke occurring 30 days after the procedure, and two major strokes both occurring well after the patient had completed TAVI. CONCLUSIONS: The use of the Claret CE Pro™ system is feasible and safe. Capture of debris in more than half of the patients provides evidence for the potential to reduce the procedural cerebral embolic burden utilising this dedicated filter system during TAVI.
No takes yet. Share an insight, caveat, or question.
Naber et al. (2012) studied Transcatheter aortic valve implantation (TAVI) (n=40). Claret CE Pro cerebral protection device was evaluated on Technical success rate. The Claret CE Pro cerebral protection device was feasible during TAVI, with a technical success rate of 60% for the first-generation and 87% for the second-generation device.
Synapse has enriched 10 related papers. Consider them for comparative context: